Cellectar Biosciences Q1 2026 Earnings Report

Cellectar Biosciences EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.89
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Cellectar Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $8.00 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Cellectar Biosciences Announcement Details

• Quarter: Q1 2026
• Date: 5/14/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, May 14, 2026
• Conference Call Time: 8:30AM ET

Cellectar Biosciences (NASDAQ:CLRB) is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma. In addition to its therapeutic pipeline, Cellectar has developed CLR 1501 and CLR 1502, fluorescent and near‐infrared imaging probes that enhance intraoperative tumor detection and surgical guidance. These imaging agents are intended to help surgeons distinguish cancerous tissue from healthy tissue in real time.

Founded in 2007 and headquartered in Madison, Wisconsin, Cellectar Biosciences conducts its research and development primarily in the United States. Preclinical and clinical studies have demonstrated the selective uptake and prolonged retention of its PDC compounds in tumor cells, supporting the potential of its platform across a range of oncologic indications. The company collaborates with academic centers and contract research organizations to advance its clinical programs.

Under the leadership of President and Chief Executive Officer Will Berry, Cellectar Biosciences is advancing its pipeline and engaging with regulatory agencies to support future product commercialization. The company continues to explore strategic partnerships and funding opportunities to further develop its PDC technology for both therapeutic and diagnostic applications in oncology.